Article Sidebar
Views PDF: 37
CLINICAL CASE REPORT OF PEMBROLIZUMAB COMBINED WITH CHEMOTHERAPY IN A PATIENT WITH ADVANCED HEAD AND NECK CANCER AFTER CHEMORADIOTHERAPY
Main Article Content
Abstract
Recurrent or metastatic head and neck cancer is associated with a poor prognosis, with a median overall survival of approximately 7–10 months when treated with cisplatin-based chemotherapy. The advent of immunotherapy has opened new therapeutic options for this patient population. We report the case of a 62-year-old male patient diagnosed with hypopharyngeal carcinoma with progressive cervical lymph node disease after concurrent chemoradiotherapy. The patient was treated with a regimen of cisplatin and 5-fluorouracil combined with pembrolizumab. After six treatment cycles, the patient showed marked clinical improvement, and computed tomography imaging demonstrated a significant reduction in tumor size
Article Details
Keywords
head and neck cancer, immunotherapy, pembrolizumab.
References
2. FN de Carvalho, et al. Disparities in stage at diagnosis of head and neck tumours: a global registry-based analysis. Lancet Regional Health – Americas. 2025
3. Lau A, Yang WF, Li KY, Su YX. Systemic Therapy in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma- A Systematic Review and Meta-Analysis. Crit Rev Oncol Hematol. 2020;153:102984.
4. Kainickal CT, Aparna MP, Kumar RR, et al. Targeted therapy in recurrent or metastatic head and neck carcinoma. Hos Pal Med Int Jnl 2018; 2: 71-76.
5. Burtness B, Harrington KJ, Greil R, et al. KEYNOTE-048 Investigators. Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study. Lancet. 2019;394:1915–1928.
6. Cohen EEW, Bell RB, Bifulco CB, et al. The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of squamous cell carcinoma of the head and neck (HNSCC) J Immunother Cancer. 2019;7:184.